Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy

Critical Reviews in Oncology/Hematology

Volumn 61, Issue 1, 2007, Pages 44-51

  Thomas, Melanie B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biliary tract cancer; Chemotherapy; Gallbladder; Molecular carcinogenesis; Transgenic models

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; GW 2974; GW 527016; IMATINIB; LAPATINIB; MITOMYCIN C; PERTUZUMAB; PROSTAGLANDIN SYNTHASE; RAPAMYCIN; SORAFENIB; TRASTUZUMAB;

BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TARGETING; GALLBLADDER CANCER; HUMAN; NONHUMAN; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DRUG DELIVERY SYSTEMS; GALLBLADDER NEOPLASMS; HUMANS; WORLD HEALTH;

EID: 33845296152     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.07.006     Document Type: Review

References (109)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 1 (2005) 10-30
2. Shaib Y.H., Davila J.A., McGlynn K., and El-Serag H.B. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 40 3 (2004) 472-477
3. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 24 2 (2004) 115-125
4. Jarnagin W.R., Fong Y., DeMatteo R.P., Gonen M., Burke E.C., Bodniewicz B.S.J., et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234 4 (2001) 507-517 [discussion 517-9]
5. Jarnagin W.R. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 19 2 (2000) 156-176
6. Vitetta L., Sali A., Little P., Nayman J., and Elzarka A. Primary "brown pigment" bile duct stones. HPB Surg 4 3 (1991) 209-220 [discussion 221-2]
7. Vitetta L., Sali A., Little P., and Mrazek L. Gallstones and gall bladder carcinoma. Aust NZ J Surg 70 9 (2000) 667-673
8. Hohaus T., Hellmich G., Freitag M., and Ludwig K. Gallbladder carcinoma-an unexpected finding after laparoscopic cholecystectomy. Zentralbl Chir 123 Suppl 2 (1998) 80-83
9. Hohaus T., Hellmich G., and Ludwig K. [Incidental gallbladder carcinoma-a report of experiences after 1,200 laparoscopic cholecystectomies]. Zentralbl Chir 122 2 (1997) 103-107
10. Yildirim E., Celen O., Gulben K., and Berberoglu U. The surgical management of incidental gallbladder carcinoma. Eur J Surg Oncol 31 1 (2005) 45-52
11. Sasatomi E., Tokunaga O., and Miyazaki K. Precancerous conditions of gallbladder carcinoma: overview of histopathologic characteristics and molecular genetic findings. J Hepatobiliary Pancreat Surg 7 6 (2000) 556-567
12. Hasumi A., Matsui H., Sugioka A., Uyama I., Komori Y., Fujita J., et al. Precancerous conditions of biliary tract cancer in patients with pancreaticobiliary maljunction: reappraisal of nationwide survey in Japan. J Hepatobiliary Pancreat Surg 7 6 (2000) 551-555
13. Chen R.F., Li Z.H., Zou S.Q., and Chen J.S. Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 4 1 (2005) 71-74
14. Chapman R.W. Risk factors for biliary tract carcinogenesis. Ann Oncol 10 Suppl 4 (1999) 308-311
15. Monte M.J., Palomero F., Sainz G.R., Dominguez M., Diez M., Torano A., et al. Bile acid secretion during rat liver carcinogenesis. Life Sci 66 12 (2000) 1085-1095
16. Yoon J.H., Higuchi H., Werneburg N.W., Kaufmann S.H., and Gores G.J. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122 4 (2002) 985-993
17. Yoon J.H., Werneburg N.W., Higuchi H., Canbay A.E., Kaufmann S.H., Akgul C., et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res 62 22 (2002) 6500-6505
18. Andrea C., and Francesco C. Squamous-cell and non-squamous-cell carcinomas of the gallbladder have different risk factors. Lancet Oncol 4 7 (2003) 393-394
19. Akcali Z., Ozyilkan O., Sakalli H., Bal N., and Noyan T. Gallbladder adenosquamous cell carcinoma: report of two cases. Acta Gastroenterol Belg 68 4 (2005) 440-442
20. Fong Y., Blumgart L.H., Lin E., Fortner J.G., and Brennan M.F. Outcome of treatment for distal bile duct cancer. Br J Surg 83 12 (1996) 1712-1715
21. Hann L.E., Fong Y., Shriver C.D., Botet J.F., Brown K.T., Klimstra D.S., et al. Malignant hepatic hilar tumors: can ultrasonography be used as an alternative to angiography with CT arterial portography for determination of resectability?. J Ultrasound Med 15 1 (1996) 37-45
22. Hann L.E., Fong Y., Shriver C.D., Botet J.F., Brown K.T., Klimstra D.S., et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. Am J Roentgenol 167 4 (1996) 1017-1021
23. Kuvshinoff B.W., Fong Y., and Blumgart L.H. Proximal bile duct tumors. Surg Oncol Clin N Am 5 2 (1996) 317-336
24. de Aretxabala X.A., Roa I.S., Burgos L.A., Araya J.C., Villaseca M.A., and Silva J.A. Curative resection in potentially resectable tumours of the gallbladder. Eur J Surg 163 6 (1997) 419-426
25. de Aretxabala X.A., Roa I.S., Mora J.P., Orellana J.J., Riedeman J.P., Burgos L.A., et al. Laparoscopic cholecystectomy: its effect on the prognosis of patients with gallbladder cancer. World J Surg 28 6 (2004) 544-547
26. de Aretxabala X.A., Roa I.S., and Burgos L. Gallbladder cancer, management of early tumors. Hepatogastroenterology 46 27 (1999) 1547-1551
27. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 9255 (2001) 539-545
28. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
29. Dubois R.N., Abramson S.B., Crofford L., Gupta R.A., Simon L.S., Van De Putte L.B., et al. Cyclooxygenase in biology and disease. FASEB J 12 12 (1998) 1063-1073
30. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53 (2002) 35-57
31. Williams C.S., Mann M., and DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18 55 (1999) 7908-7916
32. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90 21 (1998) 1609-1620
33. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90 20 (1998) 1529-1536
34. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 4 (1994) 1183-1188
35. Hayashi N., Yamamoto H., Hiraoka N., Dono K., Ito Y., Okami J., et al. Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology 34 4 Pt 1 (2001) 638-650
36. Hayashi N., Yamamoto H., Hiraoka N., Dono K., Ito Y., and Okami J. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36 2 (2002) 439-450
37. Chariyalertsak S., Sirikulchayanonta V., Mayer D., Kopp-Schneider A., Furstenberger G., Marks F., et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut 48 1 (2001) 80-86
38. Sirica A.E., Lai G.H., and Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol 16 4 (2001) 363-372
39. Nzeako U.C., Guicciardi M.E., Yoon J.H., Bronk S.F., and Gores G.J. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 35 3 (2002) 552-559
40. Vadlamudi R., Mandal M., Adam L., Steinbach G., Mendelsohn J., and Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18 2 (1999) 305-314
41. Ito Y., Takeda T., Sasaki Y., Sakon M., Yamada T., Ishiguro S., et al. Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma. Pathol Res Pract 197 2 (2001) 95-100
42. Voravud N., Foster C.S., Gilbertson J.A., Sikora K., and Waxman J. Oncogene expression in cholangiocarcinoma and in normal hepatic development. Human Pathol 20 12 (1989) 1163-1168
43. Sirica A.E., Radaeva S., and Caran N. NEU overexpression in the furan rat model of cholangiocarcinogenesis compared with biliary ductal cell hyperplasia. Am J Pathol 151 6 (1997) 1685-1694
44. Chow N.H., Huang S.M., Chan S.H., Mo L.R., Hwang M.H., and Su W.C. Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. Anticancer Res 15 3 (1995) 1055-1059
45. Sirica A.E., Lai G.H., Endo K., Zhang Z., and Yoon B.I. Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets. Semin Liver Dis 22 3 (2002) 303-313
46. Kiguchi K., Carbajal S., Chan K., Beltran L., Ruffino L., Shen J., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res 61 19 (2001) 6971-6976
47. Bol D., Kiguchi K., Beltran L., Rupp T., Moats S., Gimenez-Conti I., et al. Severe follicular hyperplasia and spontaneous papilloma formation in transgenic mice expressing the neu oncogene under the control of the bovine keratin 5 promoter. Mol Carcinog 21 1 (1998) 2-12
48. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8 3 (2002) 289-293
49. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 4 (1999) 1193-1226
50. Kiguchi K., Ruffino L., Kawamoto T., Ajiki T., and Digiovanni J. Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma. Clin Cancer Res 11 15 (2005) 5572-5580
51. Hirata A., Hosoi F., Miyagawa M., Ueda S., Naito S., Fujii T., et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res 65 10 (2005) 4253-4260
52. Diermeier S., Horvath G., Knuechel-Clarke R., Hofstaedter F., Szollosi J., and Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304 2 (2005) 604-619
53. Chan C.T., Metz M.Z., and Kane S.E. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat 91 2 (2005) 187-201
54. Kirchhoff T., Zender L., Merkesdal S., Frericks B., Malek N., Bleck J., et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 11 8 (2005) 1091-1095
55. Kubicka S. Cholangiocellular and gallbladder carcinoma. Z Gastroenterol 42 5 (2004) 397-402
56. Kubicka S., Rudolph K.L., Tietze M.K., Lorenz M., and Manns M. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 48 39 (2001) 783-789
57. Sanz-Altamira P.M., Ferrante K., Jenkins R.L., Lewis W.D., Huberman M.S., and Stuart K.E. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82 12 (1998) 2321-2325
58. Taieb J., Lecomte T., Ezenfis J., Artru P., Mitry E., Boige V., et al. 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer. Gastroenterol Clin Biol 26 6-7 (2002) 605-609
59. Knox J.J., Hedley D., Oza A., Feld R., Siu L.L., Chen E., et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23 10 (2005) 2332-2338
60. Raderer M., Hejna M.H., Valencak J.B., Kornek G.V., Weinlander G.S., Bareck E., et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 56 3 (1999) 177-180
61. Glimelius B., Ekstrom K., Hoffman K., Graf W., Sjoden P.O., Haglund U., et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8 2 (1997) 163-168
62. Thongprasert S., Napapan S., Charoentum C., and Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 16 2 (2005) 279-281
63. Okada S., Ishii H., Nose H., Yoshimori M., Okusaka T., Aoki K., et al. A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology 51 6 (1994) 515-517
64. Nakazawa K., Dobashi Y., Suzuki S., Fujii H., Takeda Y., and Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206 3 (2005) 356-365
65. Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., et al. Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J Cell Biochem 97 4 (2006) 724-734
66. Iznaga-Escobar N., Torres L.A., Morales A., Ramos M., Alvarez I., Perez N., et al. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin. I. Biodistribution and dosimetry for radioimmunotherapy. J Nucl Med 39 1 (1998) 15-23
67. Lee C.S. Transforming growth factor alpha immunoreactivity in human gallbladder and extrahepatic biliary tract tumours. Eur J Surg Oncol 24 1 (1998) 38-42
68. Lee C.S., and Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract 191 11 (1995) 1087-1091
69. Malik I.A. Gallbladder cancer: current status. Exp Opin Pharmacother 5 6 (2004) 1271-1277
70. Ogo Y., Nio Y., Yano S., Toga T., Koike M., Hashimoto K., et al. Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma. Anticancer Res 26 1B (2006) 763-770
71. Valerdiz-Casasola S. Expression of epidermal growth factor receptor in gallbladder cancer. Human Pathol 25 9 (1994) 964-965
72. Zhou Y.M., Li Y.M., Cao N., Feng Y., and Zeng F. Significance of expression of epidermal growth factor (EGF) and its receptor (EGFR) in chronic cholecystitis and gallbladder carcinoma. Ai Zheng 22 3 (2003) 262-265
73. Matsuyama S., Kitajima Y., Sumi K., Mori D., Satoh T., and Miyazaki K. Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. Oncol Rep 11 4 (2004) 815-819
74. Varnholt H., Asayama Y., Aishima S., Taguchi K., Sugimachi K., and Tsuneyoshi M. C-met and hepatocyte growth factor expression in combined hepatocellular and cholangiocarcinoma. Oncol Rep 9 1 (2002) 35-41
75. Nakanuma Y., Harada K., Ishikawa A., Zen Y., and Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 10 4 (2003) 265-281
76. Yokomuro S., Tsuji H., Lunz III J.G., Sakamoto T., Ezure T., Murase N., et al. Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. Hepatology 32 1 (2000) 26-35
77. Terada T., Nakanuma Y., and Sirica A.E. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Human Pathol 29 2 (1998) 175-180
78. Chen C., Huang M., Yang J., Yang C., Yeh Y., and Wu H. Reappraisal of percutaneous transhepatic cholangioscopic lithotomy for primary hepatolithiasis. Surg Endosc 19 4 (2005) 505-509
79. Bajo A.M., Schally A.V., Krupa M., Hebert F., Groot K., and Szepeshazi K. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc Natl Acad Sci USA 99 6 (2002) 3836-3841
80. Tian Y., Ding R.Y., Zhi Y.H., Guo R.X., and Wu S.D. Analysis of p53 and vascular endothelial growth factor expression in human gallbladder carcinoma for the determination of tumor vascularity. World J Gastroenterol 12 3 (2006) 415-419
81. Giatromanolaki A., Koukourakis M.I., Simopoulos C., Polychronidis A., and Sivridis E. Vascular endothelial growth factor (VEGF) expression in operable gallbladder carcinomas. Eur J Surg Oncol 29 10 (2003) 879-883
82. Giatromanolaki A., Sivridis E., Koukourakis M.I., Polychronidis A., and Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gallbladder. Am J Clin Oncol 25 1 (2002) 38-41
83. Sugawara Y., Makuuchi M., Harihara Y., Noie T., Inoue K., Kubota K., et al. Tumor angiogenesis in gallbladder carcinoma. Hepatogastroenterology 46 27 (1999) 1682-1686
84. Okita S., Kondoh S., Shiraishi K., Kaino S., Hatano S., and Okita K. Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol 12 5 (1998) 1013-1018
85. Yamamoto S., Fujii K., Kitadai Y., Yamamoto S., Tsuchida A., and Kajiyama G. Expression of vascular endothelial growth factor in human gallbladder lesions. Oncol Rep 5 5 (1998) 1065-1069
86. Roa J.C., Anabalon L., Roa I., Melo A., Araya J.C., and Tapia O. Promoter methylation profile in gallbladder cancer. J Gastroenterol 41 3 (2006) 269-275
87. Lefkowitch J.H. Hepatobiliary pathology. Curr Opin Gastroenterol 19 3 (2003) 185-193
88. Wongkham S., Sheehan J.K., Boonla C., Patrakitkomjorn S., Howard M., Kirkham S., et al. Serum MUC5AC mucin as a potential marker for cholangiocarcinoma. Cancer Lett 195 1 (2003) 93-99
89. Tannapfel A., Sommerer F., Benicke M., Katalinic A., Uhlmann D., Witzigmann H., et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 52 5 (2003) 706-712
90. Isa T., Tomita S., Nakachi A., Miyazato H., Shimoji H., Kusano T., et al. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 49 45 (2002) 604-608
91. Okaro A.C., Deery A.R., Hutchins R.R., and Davidson B.R. The expression of antiapoptotic proteins Bcl-2, Bcl-X(L), and Mcl-1 in benign, dysplastic, and malignant biliary epithelium. J Clin Pathol 54 12 (2001) 927-932
92. Okaro A.C., Fennell D.A., Corbo M., Davidson B.R., and Cotter F.E. Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells. Gut 51 4 (2002) 556-561
93. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., and Farrugia D. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 64 10 (2004) 3517-3524
94. Ahn B.M., Yoon S.K., Park S.H., Han J.Y., Han N.I., Kim J.K., et al. Electron microscopic mesenchymal response in chronic viral hepatitis. Taehan Kan Hakhoe Chi 8 2 (2002) 167-172
95. Kang Y.K., Kim W.H., and Jang J.J. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Human Pathol 33 9 (2002) 877-883
96. Taniai M., Grambihler A., Higuchi H., Werneburg N., Bronk S.F., Farrugia D., et al. p16INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 123 4 (2002) 1090-1098
97. Sugimachi K., Aishima S., Taguchi K., Tanaka S., Shimada M., Kajiyama K., et al. The role of overexpression and gene amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol 35 1 (2001) 74-79
98. Cazals-Hatem D., Rebouissou S., Bioulac-Sage P., Bluteau O., Blanche H., Franco D., et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 41 2 (2004) 292-298
99. Cong W., Wu M., and Chen H. Genotyping of multiple genetic alterations of intrahepatic cholangiocarcinoma. Zhonghua Yi Xue Za Zhi 81 5 (2001) 271-273
100. Ishikawa Y., Wada I., and Fukumoto M. Alpha-particle carcinogenesis in Thorotrast patients: epidemiology, dosimetry, pathology, and molecular analysis. J Environ Pathol Toxicol Oncol 20 4 (2001) 311-315
101. Jhala N.C., Vickers S.M., Argani P., and McDonald J.M. Regulators of apoptosis in cholangiocarcinoma. Arch Pathol Lab Med 129 4 (2005) 481-486
102. Kang Y.K., Kim W.H., Lee H.W., Lee H.K., and Kim Y.I. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 79 4 (1999) 477-483
103. Kawaki J., Miyazaki M., Ito H., Nakagawa K., Shimizu H., Yoshidome H., et al. Allelic loss in human intrahepatic cholangiocarcinoma: correlation between chromosome 8p22 and tumor progression. Int J Cancer 88 2 (2000) 228-231
104. Komulainen H., Hakulinen P., Servomaa K., Makkonen K., Vasara R., Maki-Paakkanen J., et al. No consistent pattern of mutations in p53 and ras genes in liver tumors of rat treated with the drinking water mutagen 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX). Environ Mol Mutagen 36 4 (2000) 292-300
105. Nehls O., Gregor M., and Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 24 2 (2004) 139-154
106. Tangkijvanich P., Kasemsupatana K., Janchai A., Kullavanijaya P., Theamboonlers A., and Poovorawan Y. Prevalence and clinical relevance of serum anti-p53 antibodies in patients with cholangiocarcinoma. Asian Pac J Allergy Immunol 18 3 (2000) 173-176
107. Radaeva S., Ferreira-Gonzalez A., and Sirica A.E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma. Hepatology 29 5 (1999) 1453-1462
108. Benckert C., Jonas S., Cramer T., Von Marschall Z., Schafer G., Peters M., et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63 5 (2003) 1083-1092
109. Miyasaka K., Kabashima T., Hamaguchi H., Hanada T., Mitsunaga K., Maejima S., et al. Transforming growth factor-beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. Biochem Biophys Res Commun 246 3 (1998) 873-880